Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRIMSON: BI 764524 for non-proliferative diabetic retinopathy
2023-508891-12-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of BI 764524 in diabetic retinopathy (NPDR) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: ≥2-step improvement in DRSS at Week 52. Planned start Oct 2024; status: authorised.
02
Drugs
BI 764524
03
Conditions
diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on 2023-508891-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508891-12-00.